Most cited papers in Pharmaceutical Economics and Policy
What are the most cited papers in Pharmaceutical Economics and Policy?
The most cited paper in Pharmaceutical Economics and Policy is "2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS" (Paulus F. Kirchhof et al., 2016), with 6,496 citations. Next come "EQ-SD: a measure of health status from the EuroQol Group" (5,748) and "The price of innovation: new estimates of drug development costs" (4,325).
Showing 50 of 99 papers. Every paper with more than 524 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS Paulus F. Kirchhof et al. · European Heart Journal | 27 Aug 2016 | 6,496 |
| 2 | EQ-SD: a measure of health status from the EuroQol Group Rosalind Rabin, Frank de Charro · Annals of Medicine | 2001 | 5,748 |
| 3 | The price of innovation: new estimates of drug development costs Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski · Journal of Health Economics | 28 Feb 2003 | 4,325 |
| 4 | Can the pharmaceutical industry reduce attrition rates? Ismail Kola, John Richard Landis · Nature Reviews Drug Discovery | 30 Jul 2004 | 4,181 |
| 5 | How to improve R&D productivity: the pharmaceutical industry's grand challenge Steven M. Paul, Daniel S. Mytelka, Christopher T. Dunwiddie et al. · Nature Reviews Drug Discovery | 19 Feb 2010 | 3,579 |
| 6 | Innovation in the pharmaceutical industry: New estimates of R&D costs Joseph A. DiMasi, Henry G. Grabowski, Ronald W. Hansen · Journal of Health Economics | 13 Feb 2016 | 3,382 |
| 7 | Sample size of 12 per group rule of thumb for a pilot study Steven A. Julious · Pharmaceutical Statistics | Oct 2005 | 3,211 |
| 8 | 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS Marco Valgimigli et al. · European Heart Journal | 26 Aug 2017 | 3,025 |
| 9 | Can Patents Deter Innovation? The Anticommons in Biomedical Research Michael Heller, Rebecca S. Eisenberg · Science | May 1998 | 2,625 |
| 10 | Clinical development success rates for investigational drugs Michael Hay, David Wayne Thomas, John L. Craighead et al. · Nature Biotechnology | 2014 | 2,577 |
| 11 | Human ICE/CED-3 Protease Nomenclature Emad S. Alnemri, David J. Livingston, Donald W. Nicholson et al. · Cell | Oct 1996 | 2,392 |
| 12 | The influence of drug-like concepts on decision-making in medicinal chemistry Paul D. Leeson, Brian Springthorpe · Nature Reviews Drug Discovery | 31 Oct 2007 | 2,354 |
| 13 | Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data Thomas P. Van Boeckel, Sumanth Gandra, Ashvin Ashok et al. · The Lancet Infectious Diseases | 9 Jul 2014 | 2,324 |
| 14 | Pharmaceutical industry sponsorship and research outcome and quality: systematic review Joel Lexchin, Lisa A Bero, Benjamin Djulbegovic et al. · BMJ | 29 May 2003 | 2,181 |
| 15 | Real-World Evidence — What Is It and What Can It Tell Us? Rachel E. Sherman, Steven A. Anderson, Gerald J. Dal Pan et al. · New England Journal of Medicine | 7 Dec 2016 | 2,133 |
| 16 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force Don Husereau, Michael Drummond, Stavros Petrou et al. · Value in Health | Mar 2013 | 2,069 |
| 17 | The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months Björn Wettermark, Niklas Hammar, C. MichaelFored et al. · Pharmacoepidemiology and Drug Safety | 9 Aug 2006 | 1,903 |
| 18 | Developing Covid-19 Vaccines at Pandemic Speed Nicole Lurie, Melanie K. Saville, Richard J. Hatchett et al. · New England Journal of Medicine | 30 Mar 2020 | 1,661 |
| 19 | Industry sponsorship and research outcome Andreas Lundh, Joel Lexchin, Barbara J. Mintzes et al. · Cochrane Database of Systematic Reviews | 16 Feb 2017 | 1,617 |
| 20 | Estimation of clinical trial success rates and related parameters Chi Heem Wong, Kien Wei Siah, Andrew W. Lo · Biostatistics | Dec 2017 | 1,594 |
| 21 | Citation Frequency and the Value of Patented Inventions Dietmar Harhoff, Francis Narin, Frederic M. Scherer et al. · The Review of Economics and Statistics | Aug 1999 | 1,564 |
| 22 | Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018 Olivier J. Wouters, Martin McKee, Jeroen Luyten · JAMA | 3 Mar 2020 | 1,562 |
| 23 | Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs Zhibin ZC Chen, Martin J. Brodie, Danny Liew et al. · JAMA Neurology | 26 Dec 2017 | 1,562 |
| 24 | Medication Adherence P. Michael Ho, Chris L. Bryson, John S. Rumsfeld · Circulation | 15 Jun 2009 | 1,491 |
| 25 | An analysis of the attrition of drug candidates from four major pharmaceutical companies Michael J. Waring, John E. Arrowsmith, Andrew R. Leach et al. · Nature Reviews Drug Discovery | 19 Jun 2015 | 1,467 |
| 26 | Data Resource Profile: The Danish National Prescription Registry Anton Pottegård, Sigrún Alba Jóhannesdóttir Schmidt, Helle Wallach‐Kildemoes et al. · International Journal of Epidemiology | 19 Oct 2016 | 1,452 |
| 27 | Physicians and the Pharmaceutical Industry Ashley D. Wazana · JAMA | 19 Jan 2000 | 1,423 |
| 28 | Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial) Peter H. Jones, Michael H. Davidson, Evan A. Stein et al. · The American Journal of Cardiology | Jul 2003 | 1,408 |
| 29 | Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework David R. Cook, Dearg S. Brown, Robert Alexander et al. · Nature Reviews Drug Discovery | 16 May 2014 | 1,376 |
| 30 | Standing on the Shoulders of Giants: Cumulative Research and the Patent Law Suzanne Scotchmer · The Journal of Economic Perspectives | Feb 1991 | 1,347 |
| 31 | Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes James A. de Lemos, Michael A. Blazing, Stephen D. Wiviott et al. · JAMA | 14 Sep 2004 | 1,335 |
| 32 | Medication Adherence Measures: An Overview Wai Yin Lam, Paula Fresco · BioMed Research International | 2015 | 1,320 |
| 33 | EQ-5D and the EuroQol Group: Past, Present and Future Nancy J. Devlin, Richard G. Brooks · Applied Health Economics and Health Policy | 13 Feb 2017 | 1,242 |
| 34 | Lessons from 60 years of pharmaceutical innovation Bernard H. Munos · Nature Reviews Drug Discovery | Dec 2009 | 1,225 |
| 35 | Medicinal Chemistry and the Molecular Operating Environment (MOE): Application of QSAR and Molecular Docking to Drug Discovery Santiago Vilar, Giorgio Cozza, Stefano Moro · Current Topics in Medicinal Chemistry | Dec 2008 | 1,222 |
| 36 | Proofs and Prototypes for Sale: The Licensing of University Inventions Richard A. Jensen, Marie Thursby · American Economic Review | Mar 2001 | 1,191 |
| 37 | ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Richard C. Pasternak, Sidney C. Smith, C Noel Bairey-Merz et al. · Circulation | 20 Aug 2002 | 1,098 |
| 38 | Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997. Peter J.H. Jones, Stephanie D. Kafonek, Irene Laurora et al. · The American Journal of Cardiology | Mar 1998 | 1,079 |
| 39 | Principles of Educational Outreach ('Academic Detailing') to Improve Clinical Decision Making Stephen B. Soumerai · JAMA | 26 Jan 1990 | 1,059 |
| 40 | Data Mining of the Public Version of the FDA Adverse Event Reporting System Toshiyuki Sakaeda, Akiko Tamon, Kaori Kadoyama et al. · International Journal of Medical Sciences | 2013 | 1,054 |
| 41 | New uses for old drugs Curtis Robert Chong, David Sullivan · Nature | Aug 2007 | 1,007 |
| 42 | Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry Daron Acemoğlu, Joshua Linn · The Quarterly Journal of Economics | 28 Jul 2004 | 984 |
| 43 | An Introduction to Markov Modelling for Economic Evaluation Andrew H. Briggs, Mark J. Sculpher · PharmacoEconomics | 1998 | 973 |
| 44 | Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis Alexandra Cameron, Margaret A Ewen, Dennis Ross‐Degnan et al. · The Lancet | 30 Nov 2008 | 949 |
| 45 | The productivity crisis in pharmaceutical R&D Fabio Pammolli, Laura Magazzini, Massimo Riccaboni · Nature Reviews Drug Discovery | Jun 2011 | 921 |
| 46 | Estimating The Cost Of New Drug Development: Is It Really $802 Million? Christopher Adams, Van V. Brantner · Health Affairs | Mar 2006 | 918 |
| 47 | Drug development for neglected diseases: a deficient market and a public-health policy failure Patrice Trouiller, Piero Olliaro, Els Torreele et al. · The Lancet | Jun 2002 | 903 |
| 48 | The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment Pricivel M. Carrera, Hagop M. Kantarjian, Victoria Susana Blinder · CA A Cancer Journal for Clinicians | 16 Jan 2018 | 884 |
| 49 | Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons Robyn M Tamblyn · JAMA | 24 Jan 2001 | 883 |
| 50 | Prescription drug cost sharing: associations with medication and medical utilization and spending and health. Dana P Goldman, Geoffrey Joyce, Yuhui Zheng · PubMed | 4 Jul 2007 | 883 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.